novo nordisk eli lilly news - Search News

Novo Nordisk, Obesity and Gain

Barron's on MSN · 14h

Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

The Wall Street Journal · 5h

Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in rival Eli Lilly also sold off. Find out more:

Reuters on MSN · 15h

Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector

Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over Novo in the weight-loss drugs market.

12h

Eli Lilly plans to launch weight-loss drug in emerging markets this year

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

15h

Morgan Stanley sees ‘limited impact’ to Lilly shares from Novo CagriSema data

Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...

5don MSN

Novo Nordisk slashes Wegovy price for patients lacking insurance benefits

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

5don MSN

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results